Numis Securities Ltd Boosts Vectura Group PLC (VEC) Price Target to GBX 252
Vectura Group PLC (LON:VEC) had its target price lifted by Numis Securities Ltd from GBX 246 ($3.21) to GBX 252 ($3.29) in a research report report published on Monday morning. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also recently issued reports on VEC. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 250 ($3.26) target price on shares of Vectura Group PLC in a report on Thursday, May 26th. Peel Hunt reissued a buy rating and set a GBX 200 ($2.61) price objective on shares of Vectura Group PLC in a research note on Friday, August 5th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 230 ($3.00) price objective on shares of Vectura Group PLC in a research note on Thursday, July 28th. FinnCap reissued a buy rating and set a GBX 225 ($2.94) price objective on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Finally, Citigroup Inc. reissued a buy rating and set a GBX 215 ($2.81) price objective on shares of Vectura Group PLC in a research note on Thursday, July 28th. Eight analysts have rated the stock with a buy rating, Vectura Group PLC has a consensus rating of Buy and an average price target of GBX 222.25 ($2.90).
Vectura Group PLC (LON:VEC) opened at 141.10 on Monday. Vectura Group PLC has a 12 month low of GBX 122.90 and a 12 month high of GBX 200.10. The company’s market cap is GBX 579.38 million. The stock has a 50 day moving average price of GBX 140.10 and a 200 day moving average price of GBX 156.17.
In other Vectura Group PLC news, insider Derodra,Andrew sold 263,364 shares of the business’s stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of GBX 152 ($1.98), for a total transaction of £400,313.28 ($522,533.98).
Vectura Group PLC Company Profile
Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.